Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Wingard

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive careH K Holland, S P Dix, R B Geller, et al.
Bone Marrow Transplantation|November 3, 2015
Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysisM L Riches, S Trifilio, M Chen, et al.
Clinical Pharmacology and Therapeutics|December 17, 2016
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapyB Moriyama, A Owusu Obeng, J Barbarino, et al.
Bone Marrow Transplantation|March 8, 2012
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantationN S Majhail, J D Rizzo, S J Lee, et al.
Hematology/Oncology and Stem Cell Therapy|March 27, 2012
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantationN S Majhail, J D Rizzo, S J Lee, et al.
Bone Marrow Transplantation|August 1, 1997
Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiationR B Geller, S M Devine, K O'Toole, et al.
Leukemia & Lymphoma|August 1, 2002
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levelsM G Mainwaring, L M Rimsza, S F Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 4, 2000
Status of high-dose chemotherapy for breast cancer: a reviewY Nieto, R E Champlin, J R Wingard, et al.
Bone Marrow Transplantation|February 1, 1996
Association of busulfan area under the curve with veno-occlusive disease following BMTS P Dix, J R Wingard, R E Mullins, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 1997
The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxisS M Devine, R B Geller, L B Lin, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive careH K Holland, S P Dix, R B Geller, et al.
Bone Marrow Transplantation|November 3, 2015
Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysisM L Riches, S Trifilio, M Chen, et al.
Clinical Pharmacology and Therapeutics|December 17, 2016
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapyB Moriyama, A Owusu Obeng, J Barbarino, et al.
Bone Marrow Transplantation|March 8, 2012
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantationN S Majhail, J D Rizzo, S J Lee, et al.
Hematology/Oncology and Stem Cell Therapy|March 27, 2012
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantationN S Majhail, J D Rizzo, S J Lee, et al.
Bone Marrow Transplantation|August 1, 1997
Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiationR B Geller, S M Devine, K O'Toole, et al.
Leukemia & Lymphoma|August 1, 2002
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levelsM G Mainwaring, L M Rimsza, S F Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 4, 2000
Status of high-dose chemotherapy for breast cancer: a reviewY Nieto, R E Champlin, J R Wingard, et al.
Bone Marrow Transplantation|February 1, 1996
Association of busulfan area under the curve with veno-occlusive disease following BMTS P Dix, J R Wingard, R E Mullins, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 1997
The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxisS M Devine, R B Geller, L B Lin, et al.
Pageof 18